-
-
-
-
-
-
-
Blueprint Medicines Reports First Quarter 2022 Results
-
-
-
-
-
-
-
U.S. drugmaker earnings heat up this week with spotlight on vaccine news
-
-
-
-
-
-
-
Complete Donald Trump Stock Impact Guide
-
-
-
-
-
-
-
AstraZeneca buys most of Acerta for $4 billion to add cancer drug
-
-
-
-
-
-
-
Jefferies Downgrades AstraZeneca (AZN) to Underperform
-
-
-
-
-
-
-
Jefferies on Pharmaceuticals: Global Pharmaceuticals Q2'12 Earnings Preview; Where is it Safe to Hide?
-
-
-
-
-
-
-
Jefferies Cuts Price Target on POZEN Inc. (POZN) by 28.5%, Major Patent Risk
-
56,417 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All